CA
XFOR icon

Cliff Asness’s X4 Pharmaceuticals XFOR Stock Holding History

Cliff Asness’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-26,382
Closed -$50.1K – 3609
2025
Q2 		$50.1K Buy
26,382
+23,483
+810% +$96.1K ﹤0.01% 3237
2025
Q1 		$20.6K Buy
2,899
+2,004
+224% +$27.6K ﹤0.01% 3126
2024
Q4 		$19.7K Sell
895
-22,962
-96% -$366K ﹤0.01% 2847
2024
Q3 		$479K Buy
23,857
+9,722
+69% +$203K ﹤0.01% 2193
2024
Q2 		$246K Buy
14,135
+12,937
+1,080% +$423K ﹤0.01% 2346
2024
Q1 		$49.9K Sell
1,198
-4,280
-78% -$119K ﹤0.01% 2375
2023
Q4 		$138K Buy
5,478
+3,435
+168% +$83.5K ﹤0.01% 2256
2023
Q3 		$66.8K Buy
+2,043
New +$89.1K ﹤0.01% 2268

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cliff Asness's XFOR Position: Q3 2025 in Review

Cliff Asness sold out of X4 Pharmaceuticals (XFOR) in Q3 2025, closing a stake of 26,382 shares — an estimated $50.1K sold.

Cliff Asness first reported a position in XFOR in Q3 2023 and held it in 8 quarters. The position peaked at $479K in Q3 2024. 42 funds tracked by Wall St. Rank hold XFOR as of Q3 2025.

  • Cliff Asness reported no remaining X4 Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Cliff Asness sold 26,382 X4 Pharmaceuticals shares in Q3 2025, an estimated $50.1K.
  • Cliff Asness first reported a position in X4 Pharmaceuticals in Q3 2023 and held it in 8 quarters.
  • Cliff Asness's X4 Pharmaceuticals position peaked at $479K in Q3 2024.
  • 42 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2025.

Based on AQR Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.